

PRESS RELEASE

Stockholm, Sweden, 18 July 2018



The Board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme

The Annual General Meeting of [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) on 9 May 2018, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting – on a directed share issue of no more than 814,409 redeemable and convertible class C shares.

The meeting also resolved to authorise the Board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the Annual General Meeting in 2019 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share (approximately SEK 0.55).

The Board of directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 18 July – 15 September 2018.

The company currently holds 3,249,870 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, where after the number of own common shares will amount to 4,064,279.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations

Linda Holmström, Senior Communications Manager

+46 708 734 095

linda.holmstrom@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

+1 347 224 0819, +1 212 579 0506

jorgen.winroth@sobi.com

The information was released for public distribution on 18 July 2018 at 08:10 CET.

Swedish Orphan Biovitrum AB (publ)

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 8 697 20 00 | www.sobi.com